The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The subgroup analysis by age and geriatric assessment in a phase III study comparison of trastuzumab emtansine with trastuzumab, pertuzumab, and docetaxel in older patients with advanced stage HER2-positive breast cancer (JCOG1607 HERB TEA study).
 
Akihiko Shimomura
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Exact Sciences; Kyowa Kirin International; Lilly; MSD K.K; Nihon Medi-Physics; Pfizer
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/UCB Japan; Lilly Japan; Pfizer
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Gilead Sciences (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); Taiho Pharmaceutical (Inst)
 
Kenji Tamura
No Relationships to Disclose
 
Keita Sasaki
No Relationships to Disclose
 
Ryo Sadachi
No Relationships to Disclose
 
Akihiko Suto
No Relationships to Disclose
 
Masataka Sawaki
No Relationships to Disclose
 
Yasuaki Sagara
Speakers' Bureau - AstraZeneca; Chugai Pharma; Daiichi Sankyo/Japan; Eisai; Lilly; MSD; Pfizer
 
Naohito Yamamoto
No Relationships to Disclose
 
Tomoyuki Yoshiyama
No Relationships to Disclose
 
Takako Hayashi
No Relationships to Disclose
 
Eriko Tokunaga
Speakers' Bureau - AstraZeneca; Daiichi Sankyo/UCB Japan; Lilly Japan
 
Takashi Yamanaka
No Relationships to Disclose
 
Chikako Shimizu
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo/UCB Japan; Kyowa Hakko Kirin; Pfizer; Taiho Pharmaceutical
Research Funding - Lilly
 
Tadahiko Shien
Consulting or Advisory Role - Allergan; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; Lilly; Novartis; Pfizer; Taiho Pharmaceutical; Takeda
Speakers' Bureau - Allergan; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; Lilly; Nihonkayaku; Novartis; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Eisai (Inst); Nihonkayaku (Inst)
 
Hiroji Iwata
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly Japan; MSD; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; MSD; Novartis; Pfizer; Sanofi
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)